The prevalence of GDM (WHO 1999 criteria) (27) was
9.9%. Both in the intention-to-treat and per-protocol analyses,
the prevalence was lower in the treatment group (intention-totreat:
7.3% compared with 12.4%, P-difference = 0.008; OR:
0.56; 95% CI: 0.36, 0.86; and per-protocol: 7.5% compared
with 13.1%, P = 0.01; OR: 0.54; 95% CI: 0.33, 0.86) (Table 2).